Generate Biomedicines (GENB) Insider & Congress Trades

Smart money at a glance

Filings to Nov 1, 2026

Net selling: insiders sold $16K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$16K netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 1 cutEven

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about GENB filings

Are insiders buying or selling Generate Biomedicines, Inc. Common Stock (GENB) stock?

Net selling: insiders sold $16K and bought $0 of GENB stock on the open market in the 90 days to Nov 1, 2026, according to SEC Form 4 filings. $16K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Arnold, Frances (Director), who sold $16K. The latest filing was on Sep 3, 2026.

Which members of Congress have traded GENB recently?

None. No member of Congress disclosed a GENB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GENB smart-money data?

This summary uses filings available on Nov 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on GENB

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Frances Arnold, sold $16K, scheduled plan sale, filed Sep 3
Lean short · thin1 sale · $16K
1 of 1 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about GENB filings

Are insiders buying or selling Generate Biomedicines, Inc. Common Stock (GENB) stock?

Which members of Congress have traded GENB recently?

None. No member of Congress disclosed a GENB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GENB smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$114.6MSells/Trims$10.1M

Buys/Adds (2)

BR
BlackRock
Q2 2026 13F
$28.0M
bought
Signals like this: n=3224, 54% finished lower at D15, median -0.8% vs SPY -0.4%
FM
FMR LLC
Q1 2026 13F
$52.7M
bought

Sells/Trims (1)

JC
JPMorgan Chase
Q2 2026 13F
$10.1M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 6, 2026

Earnings came in 5.6% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 6, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.52-5.58% miss

-$0.49 expected

Revenue

$6.3M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 4 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 6, 2026	-$0.52est. -$0.49	-5.58%miss	$6.3MSEC filing	-37.7%from $10.1M
Mar 31, 2026Reported May 7, 2026	-$1.07est. -$0.51	-111.18%miss	$7.2MSEC filing	-18.1%from $8.8M
Jun 30, 2025Reported Aug 6, 2026	Not on file	No estimate	$10.1MSEC filing	No year-ago quarter
Mar 31, 2025Reported May 7, 2026	Not on file	No estimate	$8.8MSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $14.86
52-wk high: $22.67
High: $15.63
52-wk low: $11.00
Low: $14.25
Prev close: $15.77
Mkt cap: $2.02B
ROE: -81.7%
P/S: 76.4x
P/B: 4.3x
Profit margin: +0.0%
Op margin: -1134.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $2.0B

Valuation

P/S76.43
P/B4.33

Quality

Operating margin-1134.0%
ROE-81.7%
ROA-34.6%

Growth

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

53balanced

20D volatility

94%annualized

52-week range

$14.46

$11.00$22.67

20D support

$11.84recent floor

20D resistance

$16.46recent ceiling

Returns

5D +16.5%20D +5.6%60D +4.1%

Price vs moving averages

SMA20 +7.8%SMA50 -3.6%

Volume pace

0.88xvs prior 20D

Smart money at a glance

Filings to Nov 1, 2026

Net selling: insiders sold $16K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$16K netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 1 added, 1 cutEven

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about GENB filings

Are insiders buying or selling Generate Biomedicines, Inc. Common Stock (GENB) stock?

Which members of Congress have traded GENB recently?

None. No member of Congress disclosed a GENB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GENB smart-money data?

13F: filed up to 45 days late.

Smart money on GENB

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Frances Arnold, sold $16K, scheduled plan sale, filed Sep 3
Lean short · thin1 sale · $16K
1 of 1 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about GENB filings

Are insiders buying or selling Generate Biomedicines, Inc. Common Stock (GENB) stock?

Which members of Congress have traded GENB recently?

None. No member of Congress disclosed a GENB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GENB smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$114.6MSells/Trims$10.1M

Buys/Adds (2)

BR
BlackRock
Q2 2026 13F
$28.0M
bought
Signals like this: n=3224, 54% finished lower at D15, median -0.8% vs SPY -0.4%
FM
FMR LLC
Q1 2026 13F
$52.7M
bought

Sells/Trims (1)

JC
JPMorgan Chase
Q2 2026 13F
$10.1M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 6, 2026

Earnings came in 5.6% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 6, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.52-5.58% miss

-$0.49 expected

Revenue

$6.3M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 4 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 6, 2026	-$0.52est. -$0.49	-5.58%miss	$6.3MSEC filing	-37.7%from $10.1M
Mar 31, 2026Reported May 7, 2026	-$1.07est. -$0.51	-111.18%miss	$7.2MSEC filing	-18.1%from $8.8M
Jun 30, 2025Reported Aug 6, 2026	Not on file	No estimate	$10.1MSEC filing	No year-ago quarter
Mar 31, 2025Reported May 7, 2026	Not on file	No estimate	$8.8MSEC filing	No year-ago quarter

Open: $14.86
52-wk high: $22.67
High: $15.63
52-wk low: $11.00
Low: $14.25
Prev close: $15.77
Mkt cap: $2.02B
ROE: -81.7%
P/S: 76.4x
P/B: 4.3x
Profit margin: +0.0%
Op margin: -1134.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $2.0B

Valuation

P/S76.43
P/B4.33

Quality

Operating margin-1134.0%
ROE-81.7%
ROA-34.6%

Growth

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

53balanced

20D volatility

94%annualized

52-week range

$14.46

$11.00$22.67

20D support

$11.84recent floor

20D resistance

$16.46recent ceiling

Returns

5D +16.5%20D +5.6%60D +4.1%

Price vs moving averages

SMA20 +7.8%SMA50 -3.6%

Volume pace

0.88xvs prior 20D

Generate Biomedicines, Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about GENB filings

Smart money on GENB

Questions about GENB filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 5.6% below what analysts expected.

Estimated report: Nov 5, 2026, in 4 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Generate Biomedicines, Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about GENB filings

Smart money on GENB

Questions about GENB filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 5.6% below what analysts expected.

Estimated report: Nov 5, 2026, in 4 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Generate Biomedicines, Inc. Common Stock

Overview

Questions about GENB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Generate Biomedicines, Inc. Common Stock

Overview

Questions about GENB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.